Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETES

Can an implanted minipump deliver for diabetes patients?

Nature Medicine volume 28, pages 27–28 (2022)Cite this article

Subjects

The FREEDOM studies evaluated exenatide delivered via an implanted minipump in patients with type 2 diabetes; the final study evaluated cardiovascular outcomes but offers up more questions than answers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sattar, N. et al. Lancet Diabetes Endocrinol. 9, 653–662 (2021).

    Article  Google Scholar 

  2. Holman, R. R. et al. N. Engl. J. Med. 377, 1228–1239 (2017).

    Article  CAS  Google Scholar 

  3. Henry, R. R., Logan, D., Alessi, T. & Baron, M. A. Clin. Ther. 35, 634–645 (2013).

    Article  CAS  Google Scholar 

  4. Henry, R. R. et al. Diabetes Care 36, 2559–2565 (2013).

    Article  CAS  Google Scholar 

  5. Henry, R. R. et al. J. Diabetes Complications 28, 393–398 (2014).

    Article  Google Scholar 

  6. Rosenstock, J. et al. Diabetes Care 41, 333–340 (2018).

    Article  CAS  Google Scholar 

  7. Henry, R. R. et al. Diabetes Care 41, 613–619 (2018).

    Article  CAS  Google Scholar 

  8. Henry, R. et al. Diabetes Obes. Metab. 20, 638–645 (2018).

    Article  CAS  Google Scholar 

  9. Ruff, C. T. et al. Nat. Med. https://doi.org/10.1028/s41591-021-01584-3 (2021).

  10. Rubino, D. et al. JAMA 325, 1414–1425 (2021).

    Article  CAS  Google Scholar 

  11. US Department of Health and Human Services Food and Drug Administration. Fed. Regist. 86, 49334–49337 (2021).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

    John J. V. McMurray

Authors
  1. John J. V. McMurray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John J. V. McMurray.

Ethics declarations

Competing interests

The author declares payments to his employer, Glasgow University, for his work on clinical trials, consulting and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer, Theracos. Personal lecture fees: Abbott, Alkem Metabolics, AstraZeneca, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Medscape/Heart.Org, ProAdWise Communications, S & L Solutions Event Management Inc, Radcliffe Cardiology, Servier, the Corpus, Translational Medical Academy, Web MD and (as Director) the Global Clinical Trial Partners Ltd (GCTP).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McMurray, J.J.V. Can an implanted minipump deliver for diabetes patients?. Nat Med 28, 27–28 (2022). https://doi.org/10.1038/s41591-021-01628-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01628-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing